HRH1 and metabolic dysfunction-associated steatotic liver disease: For example, unlike the other diseases with antihistamines as predicted treatments, only cyproheptadine, and not the HRH1-specific drugs, is likely to be an effective treatment for non-alcoholic fatty liver disease (NAFLD) (Figure 6B).